Investigating Typhoid Fever Pathogenesis

NCT ID: NCT03067961

Last Updated: 2021-12-10

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-02-27
• Study Completion Date: 2022-09-30

Brief Summary

Typhoid fever results from infection with a bacterium called Salmonella Typhi and is a major cause of illness worldwide. It is estimated to infect 20-25 million people every year and can affect people of all ages, but is particularly common in young children. The disease is spread through contaminated food and water, and efforts to improve water quality, sanitation and hygiene will likely go a long way to reducing the global burden of disease. Unfortunately, improving access to clean water and sanitation improvements is very costly and difficult to implement on a large scale. Vaccination against typhoid fever is likely to be a cost-effective way of reducing the global disease burden. There are two vaccines currently available against typhoid fever. Whilst these vaccines provide some protection against disease (in the region of 50-70%) these vaccines are less effective in young children, who are the population group at highest risk of disease. In order to develop a new generation of typhoid vaccines it is important to have a more complete understanding of how the bacterium causes disease. In this study, the investigators are aiming to understand more about the Salmonella Typhi bacteria and how it causes disease. In particular, the investigators aim to study the importance of a toxin produced by the typhoid bacteria, called the typhoid toxin. The typhoid toxin has only recently been discovered. It is made only by the typhoid bacteria and closely related bacteria, such as paratyphoid. From studies done in the laboratory, there is evidence that the typhoid toxin is important in causing typhoid disease. It is thought that the typhoid toxin might be important in causing symptoms of typhoid disease, however the exact role of the typhoid toxin during infection in humans hasn't been studied before. Studying this might impact on the design new vaccines against typhoid.

In this study, the investigators will be undertaking a 'challenge' with two strains of the typhoid bacteria (Salmonella Typhi). This involves exposing participants to live Salmonella Typhi under defined circumstances, by asking them to swallow a solution that contains the bacteria. After the challenge the investigators closely monitor participants for a period of at least two weeks and the investigators will then treat participants with antibiotics as soon as they are diagnosed with typhoid disease. The investigators are interested in comparing the response to challenge between two strains of the typhoid bacteria that differ in the production of the typhoid toxin. This process has been undertaken by participants in previous Oxford Vaccine Group studies since 2011.

Conditions

Salmonella Typhi Infection

Keywords

Enteric fever; Typhoid; Salmonella Typhi; Challenge study; Human model of infection; Typhoid toxin

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: DOUBLE

Study Groups

Wild type S. Typhi Quailes strain

Administered by the oral route with sodium bicarbonate at a dose of 1-5x10 4 CFU.

Group Type: EXPERIMENTAL

Salmonella Typhi (S. Typhi)

Intervention Type: OTHER

Investigating the role of typhoid toxin in the pathogenesis of enteric fever

Quailes typhoid toxin knock-out

Administered by the oral route with sodium bicarbonate at a dose of 1-5x10 4 CFU.

Group Type: EXPERIMENTAL

Salmonella Typhi (S. Typhi)

Intervention Type: OTHER

Investigating the role of typhoid toxin in the pathogenesis of enteric fever

Interventions

Salmonella Typhi (S. Typhi)

Investigating the role of typhoid toxin in the pathogenesis of enteric fever

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

Participants must satisfy all of the following criteria to be considered eligible for the study:

• Agree to give informed consent for participation in the study.
• Aged between 18 and 60 years inclusive at time of challenge.
• In good health as determined by medical history, physical examination and clinical judgment of the study team.
• Agree (in the study team's opinion) to comply with all study requirements, including capacity to adhere to good personal hygiene and infection control precautions.
• Agree to allow his or her General Practitioner (and/or Consultant if appropriate), to be notified of participation in the study.
• Agree to allow study staff to contact his or her GP to access the participant's vaccination records and summary of medical history.
• Agree to allow Public Health England to be informed of their participation in the study.
• Agree to give his or her close contacts written information informing them of the participant's involvement in the study and offer them voluntary screening for S. Typhi carriage.
• Agree to have 24-hour contact with study staff during the four weeks post challenge and to be able to ensure that they are contactable by mobile phone for the duration of the challenge period until antibiotic completion.
• Agree to allow the study team to hold the name and 24-hour contact number of a close friend, relative or housemate who will be kept informed of the study participant's whereabouts for the duration of the challenge period (from the time of challenge until completion of antibiotic course). This person will be contacted if study staff are unable to contact the participant.
• Have internet access to allow completion of the e-diary and real-time safety monitoring.
• Agree to avoid antipyretic/anti-inflammatory treatment from the time of challenge (Day 0) until advised by a study doctor or until 14 days after challenge.
• Agree to refrain from donating blood for the duration of the study.
• Agree to provide their National Insurance/Passport number for the purposes of TOPS registration and bank account details for payment of reimbursement expenses.

Exclusion Criteria

The participant will not be enrolled if any of the following apply:

• History of significant organ/system disease that could interfere with trial conduct or completion. Including, for example, but not restricted to:

• Cardiovascular disease
• Respiratory disease
• Haematological disease
• Endocrine disorders
• Renal or bladder disease, including history of renal calculi
• Biliary tract disease, including biliary colic, asymptomatic gallstones or previous cholecystectomy
• Gastro-intestinal disease including requirement for antacids, H2-receptor antagonists, proton pump inhibitors or laxatives
• Neurological disease
• Metabolic disease
• Autoimmune disease
• Psychiatric illness requiring hospitalisation or known or suspected drug and/or alcohol misuse (alcohol misuse defined as an intake exceeding 42 units per week)
• Infectious disease
• Have any known or suspected impairment of immune function, alteration of immune function, or prior immune exposure that may alter immune function to typhoid resulting from, for example:

• Congenital or acquired immunodeficiency, including IgA deficiency
• Human Immunodeficiency Virus infection or symptoms/signs suggestive of an HIV-associated condition
• Receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 12 months or long-term systemic corticosteroid therapy.
• Receipt of immunoglobulin or any blood product transfusion within 3 months of study start.
• History of cancer (except squamous cell or basal cell carcinoma of the skin and cervical carcinoma in situ).
• Moderate or severe depression or anxiety as classified by the Hospital Anxiety and Depression Score at screening or challenge that is deemed clinically significant by the study doctors .
• Weight less than 50kg .
• Presence of implants or prosthesis.
• Anyone taking long-term medication (e.g. analgesia, anti-inflammatories or antibiotics) that may affect symptom reporting or interpretation of the study results.
• Contraindication to fluoroquinolone or macrolide antibiotics (e.g ciprofloxacin or azithromycin).
• Female participants who are pregnant, lactating or who are unwilling to ensure that they or their partner use effective contraception 30 days prior to challenge and until three negative stool samples have been obtained after completion of antibiotic treatment.
• Full-time, part-time or voluntary occupations involving:

• Clinical or social work with direct contact with young children (defined as those attending pre-school groups or nursery or aged under 2 years), or
• Clinical or social work with direct contact with highly susceptible patients or persons in whom typhoid infection would have particularly serious consequences (unless willing to avoid work until demonstrated not to be infected with S. Typhi in accordance with guidance from Public Health England and willing to allow study staff to inform their employer).
• Full time, part time or voluntary occupations involving:

• Commercial food handling (involving preparing or serving unwrapped foods not subjected to further heating)
• Close household contact with:

• Young children (defined as those attending pre-school groups, nursery or those aged less than 2 years)
• Individuals who are immunocompromised.
• Scheduled elective surgery or other procedures requiring general anaesthesia during the study period.
• Participants who have participated in another research study involving an investigational product that might affect risk of typhoid infection or compromise the integrity of the study within the 30 days prior to enrolment (e.g. significant volumes of blood already taken in previous study) .
• Detection of any abnormal results from screening investigations (at the clinical discretion of the study team).
• Inability to comply with any of the study requirements (at the discretion of the study staff and the participant's General Practitioner).
• Any other social, psychological or health issues which, in the opinion of the study staff, may

• put the participant or their contacts at risk because of participation in the study,
• adversely affect the interpretation of the primary endpoint data,
• impair the participant's ability to participate in the study.
• Having previously received any typhoid vaccine.
• Having been resident in an enteric fever endemic country for 6 months or more.
• Have previously been diagnosed with laboratory-confirmed typhoid or paratyphoid infection or been given a diagnosis compatible with enteric fever.
• Have participated in previous typhoid or paratyphoid challenge studies (with ingestion of challenge agent).
• Have a prolonged corrected QT interval (>450 milliseconds) on ECG screening.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Bill and Melinda Gates Foundation

OTHER

Sponsor Role: collaborator

Yale University

OTHER

Sponsor Role: collaborator

University of Oxford

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Andrew J Pollard

Role: PRINCIPAL_INVESTIGATOR

Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Oxford, Oxfordshire, United Kingdom, OX3 7LE

Locations

Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine

Oxford, Oxfordshire, United Kingdom

Countries

United Kingdom

Related Links

https://www.nature.com/articles/s41591-019-0505-4

Related Info

Other Identifiers

OVG 2016/03

Identifier Type: -

Identifier Source: org_study_id